Core Viewpoint - Haier Biomedical held the 2026 Ecological Partner Co-Creation Summit, unveiling three core strategies: AI+ Innovation, Science and Technology Co-Creation, and a New Era of Channels, while signing the "AI Autonomous Laboratory" ecological cooperation agreement with eight leading enterprises to build a new ecosystem in life sciences [2][3][12]. Group 1: AI+ Innovation Strategy - The AI+ Innovation strategy aims to reconstruct intelligent productivity in life sciences by creating an ecosystem that integrates AI, data, robotics, equipment, and applications, facilitating a transition from service processes to enhanced productivity and precision discovery [9]. - Haier Biomedical's CTO introduced the "AutoLab Mind" intelligent brain as the core of a four-layer intelligent architecture, enabling cognitive decision-making in laboratory settings and streamlining process collaboration and data management [9]. Group 2: Science and Technology Co-Creation - The Science and Technology Co-Creation strategy focuses on breaking down barriers between research and application, transforming clinical research pain points into product innovation starting points through collaboration with top research institutions and local agents [6][7]. - A roundtable forum was held to discuss how to promote Chinese solutions globally, featuring representatives from various medical and research institutions [6][7]. Group 3: New Era of Channels - The New Era of Channels strategy emphasizes the importance of ecological integration, scene responsiveness, and user operation capabilities in future competition, moving away from traditional pricing models to a user value contribution commission model [13]. - This model encourages distributors to become innovators in their fields, driving self-evolution and achieving mutual benefits [13]. Group 4: Strategic Partnerships - Haier Biomedical signed strategic cooperation agreements with eight leading enterprises, including Shunfeng Pharmaceutical and Southeast University, to accelerate the construction of a full lifecycle service loop from research to clinical application [7][10]. - The company aims to leverage these partnerships to enhance its capabilities in the life sciences sector and promote technological innovation [7][10]. Group 5: Global Business Expansion - Haier Biomedical has established a presence in over 160 countries and regions, maintaining long-term collaborations with nearly 80 international organizations, including WHO and UNICEF, positioning itself as a leader in the global life sciences laboratory equipment market [15]. - The company focuses on green development and has received multiple certifications, reinforcing its commitment to sustainable practices in the industry [15].

Core Insights - Haier Biomedical has signed a strategic cooperation agreement with Sichuan University National Key Laboratory of Biotherapy to focus on the development of the biomedical health industry, emphasizing technological innovation, product development, and market expansion [1][3]. Group 1: Strategic Collaboration - The collaboration represents a deep integration of national-level scientific research capabilities with leading industry enterprises, focusing on major diseases such as tumors and infectious diseases [3]. - The National Key Laboratory is recognized as a key innovation platform, having successfully developed the world's first mRNA vaccine for HBV-related liver cancer, which received FDA clinical trial approval in 2025 [3]. Group 2: Technological Innovation - Haier Biomedical aims to leverage AI and automation to enhance research scenarios and create a collaborative ecosystem between science and engineering [4]. - The company is not merely a supplier of equipment but acts as an "innovation partner," transforming original laboratory innovations into stable, reliable, and replicable solutions [4]. Group 3: Financial Performance - Continuous innovation has led to stable growth, with new industry revenues from smart medication and blood technology accounting for 48% of total revenue in the first three quarters of 2025 [4]. - The overseas market revenue has increased by 20.18% year-on-year, indicating significant global expansion and resilience [4]. Group 4: Future Prospects - With ongoing investments in R&D and the enhancement of collaborative ecosystems, Haier Biomedical is expected to achieve breakthroughs in high-end biomedical equipment and smart laboratory solutions [5]. - The market is anticipated to benefit from a platform-driven ecosystem that enhances innovation conversion efficiency, solidifying Haier Biomedical's investment value [5].

Investment Rating - The report maintains a "Recommended" rating for Haier Biomedical (688139) [1] Core Views - The company reported a 2.27% decline in revenue for H1 2025, totaling 1.196 billion yuan, and a 39.09% drop in net profit to 143 million yuan, primarily due to external factors and strategic investments [1][5] - New industries are showing growth, with their revenue share increasing to 47%, reflecting a 7.27% year-on-year growth, particularly in laboratory solutions and smart medication [5] - The overseas business is performing strongly, with a 30.17% increase in overseas revenue to 427 million yuan in H1 2025, while domestic revenue fell by 14.64% to 761 million yuan [5] Financial Summary - Total revenue projections for 2024A, 2025E, 2026E, and 2027E are 2,284 million, 2,630 million, 3,061 million, and 3,464 million yuan respectively, with expected growth rates of 0.1%, 15.2%, 16.4%, and 13.2% [1][6] - Net profit projections for the same years are 367 million, 423 million, 508 million, and 585 million yuan, with growth rates of -9.7%, 15.4%, 20.1%, and 15.1% [1][6] - The company’s earnings per share (EPS) is projected to increase from 1.15 yuan in 2024A to 1.84 yuan in 2027E [6]

Core Viewpoint - Haier Biomedical's stock price has seen a slight decline, with a current market capitalization of 10.346 billion yuan, ranking 36th in the medical device sector and 1786th in the A-share market [1] Group 1: Company Performance - In the first half of the year, new industries accounted for 47% of total revenue, achieving a year-on-year growth of 7.27% [4] - The company reported a total overseas revenue of 427 million yuan, reflecting a year-on-year increase of 30.17% [3][4] - The overall profitability of the company has been under pressure due to external factors, new capacity ramp-up, and strategic investments, but is expected to improve in the latter half of the year [2] Group 2: Market Position and Strategy - The company has a market share exceeding 50% in plasma collection solutions and ranks among the top three in the automated medication market [1] - The company has established localized operations in 17 countries, with its low-temperature product lines leading in market share in 25 countries [3] - The company is focusing on enhancing its R&D capabilities, with a significant increase in R&D and sales expense ratios, indicating a commitment to innovation and market expansion [2] Group 3: Future Outlook - The company anticipates improved performance in the third and fourth quarters as industry conditions warm and innovative products gain traction [2] - The domestic market is expected to recover as government investments in healthcare infrastructure are implemented, despite a current decline in revenue [5] - The company is actively developing AI-related technologies to integrate into its medical and research applications, creating a closed-loop system for efficient collaboration [6]

Core Viewpoint - Haier Biomedical's performance in the first half of the year was under pressure due to external factors, new capacity ramp-up, and strategic investments, but the overall performance is expected to improve with industry recovery and accelerated innovation [1] Group 1: Financial Performance - The company's revenue and profit in the second quarter were at their lowest for the year, with expectations for improved profitability in the third and fourth quarters [1] - New industries accounted for 47% of total revenue, showing a year-on-year growth of 7.27%, with smart medication, blood technology, and laboratory solutions each contributing approximately 11%, 11%, and 17% to total revenue respectively [2] Group 2: Market Position - Haier Biomedical's plasma collection solutions have a market share exceeding 50%, and its automated medication market share ranks among the top three in the industry [2] - The company has achieved leading positions in the domestic market for total organic carbon analyzers and UV spectrophotometers, with its biological safety cabinets ranking first nationally [2] Group 3: Overseas Business - The company achieved overseas revenue of 427 million yuan, a year-on-year increase of 30.17%, with the second quarter marking the highest quarterly revenue and growth rate in 2023 [3] - Products and solutions are applied in over 150 countries, with localized operations established in 17 countries, and three low-temperature product lines leading in market share in 25 countries [3] Group 4: AI Development - The company is enhancing its AI infrastructure with a multi-layered architecture, integrating AI technology with life sciences and medical innovation [4] - A foundational AI model, "Yingkang Brain," has been developed, focusing on various industry fields, resulting in 17 specialized AI clusters [4] - The integration of AI into medical decision-making and research experiments is being realized through automated solutions and hardware systems, creating an efficient collaboration of data, devices, and scenarios [4]

Core Viewpoint - Haier Biomedical has transformed from a single low-temperature storage manufacturer to a comprehensive life sciences and medical innovation enterprise, covering low-temperature storage, smart medication, blood technology, and laboratory solutions [1] Financial Performance - For the first half of 2025, the company achieved operating revenue of 1.196 billion yuan and a net profit attributable to shareholders of 143 million yuan [1] Business Transformation - The revenue share from new industries (smart medication, blood technology, laboratory solutions, etc.) increased from 38% in 2023 to 47% in the first half of 2025, a year-on-year increase of 7.27 percentage points [1] International Expansion - The company's products are now available in over 150 countries and regions, with five new localized platforms established in Japan, Brazil, and others during the reporting period [1] - The localized strategy has shown significant results, with overseas revenue growing by over 30% year-on-year, and the second quarter's revenue scale and growth rate reaching a new high for 2023 [1]